Last reviewed · How we verify
Preset increase in frusemide dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Preset increase in frusemide dose (Preset increase in frusemide dose) — Barts & The London NHS Trust.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Preset increase in frusemide dose TARGET | Preset increase in frusemide dose | Barts & The London NHS Trust | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Preset increase in frusemide dose CI watch — RSS
- Preset increase in frusemide dose CI watch — Atom
- Preset increase in frusemide dose CI watch — JSON
- Preset increase in frusemide dose alone — RSS
Cite this brief
Drug Landscape (2026). Preset increase in frusemide dose — Competitive Intelligence Brief. https://druglandscape.com/ci/preset-increase-in-frusemide-dose. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab